Clinical Trial Update: A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating the safety of Pozelimab in pediatric participants aged 1 to 5 years with CHAPLE disease, and it is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chaple Disease

Drugs mentioned

• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: CHAPLE Disease | Phase 4 | Status: RECRUITING